AC
ABMD

Ascend Capital’s Abiomed Inc ABMD Stock Holding History

Ascend Capital’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$8.19M Buy
+18,215
New +$7.18M 0.41% 74

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Ascend Capital's ABMD Position: Q3 2018 in Review

Ascend Capital opened a new position in Abiomed Inc (ABMD) in Q3 2018: 18,215 shares worth $8.19M. The stake represents 0.41% of the portfolio and ranks #74 among its holdings.

529 funds tracked by Wall St. Rank hold ABMD as of Q3 2018.

  • Ascend Capital held 18,215 shares of Abiomed Inc worth $8.19M as of Q3 2018.
  • Abiomed Inc was a new Ascend Capital position in Q3 2018.
  • Abiomed Inc made up 0.41% of Ascend Capital's portfolio in Q3 2018, its #74 holding.
  • 529 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.